Literature DB >> 11796366

In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Sheila Malay1, Patricia M Roblin, Tamara Reznik, Andrei Kutlin, Margaret R Hammerschlag.   

Abstract

The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11796366      PMCID： PMC127069          DOI： 10.1128/AAC.46.2.517-518.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

3.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 5.  Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.

Authors:  M R Hammerschlag
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

6.  In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  J P Maskell; A C Whiley; A M Sefton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  J Chemother       Date:  1997-02       Impact factor: 1.714

Review 8.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

10.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191
  10 in total
  7 in total

1.  In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.

Authors:  Jan Rupp; Andreas Gebert; Werner Solbach; Matthias Maass
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity.

Authors:  Pavel Bobrovsky; Valentin Manuvera; Nadezhda Polina; Oleg Podgorny; Kirill Prusakov; Vadim Govorun; Vassili Lazarev
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

4.  Mycoplasma genitalium: should we treat and how?

Authors:  Lisa E Manhart; Jennifer M Broad; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

5.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.

Authors:  Raymond P Smith; Aldona L Baltch; William J Ritz; Andrea N Carpenter; Tanya A Halse; Lawrence H Bopp
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.

Authors:  Satoshi Ameyama; Yuko Shinmura; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.